...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature clinical practice. Oncology >Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
【24h】

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

机译：药物洞察力：分子靶向药物在癌症治疗中对胃肠道和肝脏的不良影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent advances in the understanding of molecular mechanisms of cancer have led to the development of novel compounds that target specific cancer pathways. These drugs encompass monoclonal antibodies and tyrosine and non-tyrosine kinase inhibitors, and have been approved by the FDA and the European Medicines Agency, among others, for cancer treatment. These agents are associated with several toxic effects including potentially unacceptable gastrointestinal adverse effects. Diarrhea and hepatotoxicity, the most common adverse events experienced with these treatments, can frequently lead to treatment discontinuation and consequently decreased cancer control. We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event.
机译：在了解癌症分子机制方面的最新进展已导致开发针对特定癌症途径的新型化合物。这些药物包括单克隆抗体，酪氨酸和非酪氨酸激酶抑制剂，并已获得FDA和欧洲药品管理局的批准，可用于癌症治疗。这些药物与多种毒性作用有关，包括潜在的胃肠道不良反应。腹泻和肝毒性是这些治疗方法最常见的不良反应，经常会导致治疗中断并因此导致癌症控制降低。我们回顾了主要的分子靶向疗法引起的胃肠道和肝脏毒性作用的发生率和临床模式，并对每种不良事件的起因提出了一些假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号